ReviewCurrent treatment options in oncology2026
Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
opinion statementLung cancer remains the leading cause of cancer-related mortality. The 5-year survival rate for advanced non-small cell lung cancer (NSCLC) is only 20%-30%, highlighting an urgent need for more effective therapeutic strategies. Immune checkpoint inhibitors and anti-angiogenic agents are now widely used in clinical practice and have significantly prolonged patient survival. However, their efficacy and safety remain constrained by multiple reasons. This review systematically outlines the synergistic mechanisms and recent advances of combined anti-PD-1/PD-L1 and anti-angiogenic therapy. It also evaluates the clinical value of novel bispecific antibodies in NSCLC, with a specific focus on their potential advantages in patients with comorbidities. By systematically synthesizing preclinical and clinical data from 2020 to 2026, this article analyzes the mechanistic roles of the combination strategy. The clinical efficacy and safety profile are comprehensively assessed. Current evidence demonstrates that combining anti-PD-1/PD-L1 agents with anti-angiogenic therapy synergistically remodels the tumor immune microenvironment. This approach enhances T cell infiltration and function and effectively overcomes monotherapy resistance. Clinical studies have confirmed that this regimen extends median overall survival (mOS) by 4.8 months. Bispecific antibodies developed on this foundation optimize pharmacokinetic matching and improve safety profiles. These single-agent therapies show promising clinical potential for managing NSCLC with chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF). In conclusion, combined therapy has become a pivotal direction in NSCLC systemic treatment. Future research should prioritize optimizing treatment regimens, refining real-world safety assessments, and expanding clinical application in patients with complex comorbidities to address current unmet therapeutic needs.
Indexed as
Identifiers
42696184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.